Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M

Clearside Biomedical, Inc.

Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.
Authorized shares reduced from 400M to 26,666,666; no change to par value.
Trading on split-adjusted basis on Nasdaq Capital Market starting Sept 15, 2025; new CUSIP 185063203.
No fractional shares; cash paid in lieu; proportionate adjustments to stock options, RSUs, warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Clearside Biomedical, Inc.: Clearside Biomedical filed a Certificate of Amendment to effect a 1-for-15 reverse stock split and reduce authorized common shares from 400,000,000 to 26,666,666 (effective 2025-09-12).

Change: charter amendment
Effective: 2025-09-12

Exact text from the filing

On September 10, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the “ Shares Reduction ”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-114089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.